Endometrial carcinoma is associated with which of the following suppression gene mutation
Endometrial carcinoma, particularly the endometrioid subtype, is often associated with mutations in certain genes. The most well-known is PTEN, which is a tumor suppressor gene located on chromosome 10. PTEN mutations lead to loss of function, which disrupts the PI3K/AKT/mTOR signaling pathway, promoting cell proliferation and survival. This is part of the PI3K pathway's role in cancer development.
Now, looking at the options provided (though they are labeled A-D without specifics), the correct answer should be PTEN. Let's assume the options include PTEN and other genes like TP53, BRCA1/2, or others. For example, if the options are A. TP53, B. BRCA1, C. PTEN, D. RB1, then the correct answer is C. PTEN.
Why are the other options incorrect? TP53 is involved in many cancers but is more associated with Li-Fraumeni syndrome and is a common mutation in various tumors, including some endometrial cancers, but not the most specific. BRCA1 and BRCA2 are linked to hereditary breast and ovarian cancer, not typically endometrial. RB1 is associated with retinoblastoma and other cancers but not endometrial.
The clinical pearl here is that PTEN mutations are a hallmark of endometrioid endometrial carcinoma, especially in the context of Lynch syndrome, which is a hereditary cancer syndrome. Students should remember that PTEN is a key player in this type of cancer and is part of the PI3K pathway. Also, endometrial cancer is part of Lynch syndrome, which involves mutations in DNA mismatch repair genes, but the question specifically asks about a tumor suppressor gene, so PTEN fits here.
**Core Concept**
Endometrial carcinoma, particularly the endometrioid subtype, is strongly associated with **PTEN** tumor suppressor gene mutations. This gene regulates the PI3K/AKT/mTOR signaling pathway, which controls cell growth and apoptosis. Loss of PTEN function promotes uncontrolled cell proliferation.
**Why the Correct Answer is Right**
**PTEN (Phosphatase and Tensin Homolog)** is the most commonly mutated tumor suppressor gene in endometrioid endometrial carcinoma (~40–60% cases). It dephosphorylates PIP3, antagonizing the PI3K/AKT/mTOR pathway. Mutations in PTEN lead to constitutive activation of this pathway, driving tumorigenesis. It is also a key component of the **POLE (POLE p.S297F)** and **microsatellite instability (MSI)** subtypes of endometrial cancer.
**Why Each Wrong Option is Incorrect**
**Option A:** **TP53** mutations are more common in serous endometrial carcinoma and are associated with poor prognosis, not endometrioid type.
**Option B:** **BRCA1/BRCA2** mutations are linked to hereditary breast and ovarian cancer syndrome,